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Stax™ Hyperion Flow Technology 
+ New Development 
Pipeline 
Trends in Continuous Bioprocessing 
• Process economics: 
– Improved capital utilization 
• Reduced facility footprint 
– Reduction of operating expenses 
– Increased capacity utilization 
 
• Process control: 
– Improved safety 
– Improved product quality control 
BioSMB® Technology 
Key Benefits: 
 Improved specific productivity 
 Improved utilization of resin capacity 
 Significant reduction in buffer consumption 
 Enabler for integrated continuous bioprocessing 
 Enabler for integrated single-use manufacturing 
BioSMB Technology 
Highlights: 
• Multiple columns work together to 
allow continuous feed 
• Columns travel through the 
process (or actually vice versa) 
• Each column results in one elution 




UV Absorbance in Product Outlet 
Evaluation of Chromatographic 
Performance 







Process performance monitoring Comment 
Column characterization (HETP and asymmetry) Prior to process start 
Critical parameters (pool volumes, yields, etc.) Off-line analyses 
Review of chromatographic peaks: 
• Visual review 
• Moment analysis 
Based on on-line data 
This Strategy may need to be reconsidered 
for Continuous Bioprocessing 
Using old Tools for a new Approach 
Multivariate Data Analysis (MVDA): 
 A mathematical tool for data reduction 
 Very strong for recognizing patterns in large and complex datasets 
 Principal Components Analysis (PCA) 
Raw Data 1st PC 2nd PC 
Courtesy: Umetrics (http://www.umetrics.com) 
PCA for Chromatography 
The correlation between the Principal Components (PC1 & PC2) and 
the physical characteristic of the chromatography peak... 
Case Study 1: Column to Column Variations 
 
Monovariate Analysis Multivariate Analysis 
No significant variations detectable Main source for variation: Column-
to-column variations 
Protein A Elution Peaks (UV) 
Data generated at Boehringer Ingelheim, 
Fremont, CA (courtesy) 
Case Study 1: Batch to Batch Variations 
 
Monovariate Analysis Multivariate Analysis 
No significant variations detectable Reasonable consistency for two, 





Protein A Elution Peaks (UV) 
Data generated at Boehringer Ingelheim, 
Fremont, CA (courtesy) 
Case Study 1: Batch to Batch Variations 
 
Monovariate Analysis Multivariate Analysis 
Too much data to make any sense Harvest procedures impacted the 
PCA of PrA elution peaks 
Three different harvests with different 
cultivation procedures 
Three different clouds 
Protein A Elution Peaks (UV) 
Data generated at Boehringer Ingelheim, 
Fremont, CA (courtesy) 
Case Study 2: Column Malfunctioning 
 
Monovariate Analysis Multivariate Analysis 
Cycle-to-cycle overlay shows some 
effect in Column 5 
Column 5 shows deviations from 
start of run 
Data generated at Sanofi-Aventis, 
Höchst, Germany (courtesy) 
Note: Performance decay in Column 5 was most 
likely related to inadequate cleaning conditions 
(not to the separation and/or technology itself) 
Protein A Elution Peaks (UV) 
Protein A Elution Peaks (UV) 
Monovariate Analysis Multivariate Analysis 
Overall process performance was 
consistently acceptable 
Small differences process 
conditions become clearly visible 
Case Study 3: Comparing Processes 
Eight tests: 
• Two monoclonal antibody products 
• Same chromatography media and 
buffer system 
• Slight differences in load capacity 
• Different column configurations in 
load zone 
• Elution peaks looked very similar 
Molecule A 
Molecule B 
Case Study 4: Process upsets 
 
Monovariate Analysis Multivariate Analysis 
Several process interruptions for 
changing feed solutions and buffers 
Excursions in PCAs correlated with 
changing feed solutions 
Opportunities 







• Correlating response from MVDA to product attributes (CQA’s) will bring 
us one step closer to parametric release 
• Integrated process control (Process Analytical Technologies) 
 
Opportunity (examples only) Potential Approach 
On-line column characterization PCA on DP across columns (e.g. 
during equilibration or wash step) 
Monitoring bed packing consistency PCA on conductivity as column 
moves through different wash steps 
Conclusions 
• Multivariate Data Analysis (MVDA) turns large datasets into (visual) 
information, thereby capturing the value of continuous bioprocessing 
• Principal Components Analysis (PCA) can detect small deviations in 
peak shapes before traditional methods can: 
– Monitor process consistency (cycle-to-cycle reproducibility) 
– Detect column-to-column variations 




 MVDA will help end-users providing evidence 
that they’re in control of their process 
 MVDA can be used to build effective process 
monitoring and control strategies  
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